Jump to content

VRX - Valeant Pharmaceuticals International Inc.


giofranchi
[[Template core/global/global/poll is throwing an error. This theme may be out of date. Run the support tool in the AdminCP to restore the default theme.]]

Recommended Posts

there is no fuc*&%$ing way that earnings are going to just grow 15%... and the stock only be at $400 because that assumes they make virtually no other acquisitions (or just very small tuck-ins).

 

original mungerville,

I just post articles about the businesses I follow... to me they are simply pieces of information... it certainly doesn't mean I agree with everything that is written in those articles! ;)

 

Cheers,

 

Gio

Link to comment
Share on other sites

  • Replies 6.1k
  • Created
  • Last Reply

Top Posters In This Topic

there is no fuc*&%$ing way that earnings are going to just grow 15%... and the stock only be at $400 because that assumes they make virtually no other acquisitions (or just very small tuck-ins).

 

original mungerville,

I just post articles about the businesses I follow... to me they are simply pieces of information... it certainly doesn't mean I agree with everything that is written in those articles! ;)

 

Cheers,

 

Gio

 

Gio,

 

That was already understood. In no way did I assume you agreed with the entire article!

 

I just was trying to provide a helpful critique of the article - that's all. At its essence, its the same point Ackman is making, the article is giving little to no value to the platform value of Valeant.

Link to comment
Share on other sites

Gio,

 

That was already understood. In no way did I assume you agreed with the entire article!

 

;)

 

I just was trying to provide a helpful critique of the article - that's all. At its essence, its the same point Ackman is making, the article is giving little to no value to the platform value of Valeant.

 

+1!

 

Gio

Link to comment
Share on other sites

So apparently ValueAct sold 20% of its Valeant stake. Most people seem to be guessing that they might want to buy some FOX with it, or maybe PCP.

 

Mr. Market is going to freak out, of course, despite the fact that ValueAct still has a huge 3.6bn stake that represent a huge part of its AUM and that its cost basis was peanuts and at some point they were going to need to raise cash for other opportunities.

 

Could be a buying opportunity if the over-reaction is big enough.

 

http://www.newswire.ca/en/story/1553919/valueact-capital-discloses-sale-of-shares-of-valeant-pharmaceuticals-international-inc

 

ValueAct Capital Management, L.P. announced today that it has sold 4.2 million shares of Valeant Pharmaceuticals International, Inc. (NYSE: VRX; TSX: VRX) in brokers' transactions on the NYSE.

 

ValueAct Capital's CEO Jeffrey W. Ubben said: "Mike Pearson and the Valeant team's exceptional performance have once again caused our investment in Valeant to grow in value to well above 20% of our funds' assets, and we are again compelled to reduce our position to rebalance our overall portfolio.  We have owned Valeant shares for over nine years and have sold shares on three previous occasions for the same portfolio management purposes. After this sale, our investment in Valeant will continue to be well in excess of $3.0bn and will be one of the largest investments in our funds. I look forward to continuing to work with Mike and my fellow members of the Board of Directors."

Link to comment
Share on other sites

Market seems to like it.

 

Either that, or the selling pressure from ValueAct is gone so it's back to climbing. Probably a bit of both.

 

Actually Pearson alluded to this in one of the recent interviews ... said something like our problem is that our large shareholders end up overweight and always have to sell! Its tough when you have so much success!

Link to comment
Share on other sites

http://www.bloomberg.com/news/articles/2015-06-16/valeant-said-in-advanced-talks-to-buy-egypt-drugmaker-amoun

 

Valeant Pharmaceuticals International Inc. is in advanced negotiations to acquire Egyptian drugmaker Amoun Pharmaceutical Co. as it seeks to expand into emerging markets, according to people with knowledge of the matter.

 

The drugmaker, based in Laval, Quebec, may reach an agreement with Amoun’s shareholders in the coming weeks, the people said, asking not to be identified as the information is private. No final decision has been made and any deal may still fall apart, they said.

 

A sale of Amoun could value the company at $700 million to $800 million, people familiar with the matter said in May.

Link to comment
Share on other sites

 

WSJ: "Breaking: Valeant has made a preliminary takeover approach to animal-health company Zoetis."

 

Never boring (if true).

 

Ah!... I think I saw this coming... Though I would not have imagined it might have come so soon! ;)

 

Cheers,

 

Gio

Link to comment
Share on other sites

Well, I am skeptical that this is real.  I see absolutely no reason to trade VRX equity for ZTS.  I haven't done tons of work on ZTS, but from my analysis it appears to be a structurally lower gross margin business than VRX base business, much less Salix.  Plus, the organic growth of ZTS seems lower than even a more normalized VRX organic growth rate, much less the growth rate that is going to exist the next few years with Salix.  Even if you cut SG&A and R&D, I doubt that will get you to the VRX target margin (i.e. 50% Adj EBITDA).

 

So, why would Pearson trade VRX equity, representing higher growth and higher margin, for ZTS equity which is lower margin and lower growth when ZTS already has a big takeout premium baked into the valuation?  I would seriously question my VRX investment if this deal is real.

 

 

 

Link to comment
Share on other sites

can anyone come up with a way i can understand VRX's valuation? I know there's a great capital allocator at the helm, Ackman thinks shares are undervalued, and the company doesn't want to issue stock... I just don't understand why VRX is worth $100B enterprise value.

Link to comment
Share on other sites

 

Why don't you short it? ;)

 

I'm sure that Ackman, Sequoia, ValueAct, Glenn Grenberg, and Lou Simpson are all incapable of doing due diligence and looking through accounting to real economics...

Link to comment
Share on other sites

 

Why don't you short it? ;)

 

I'm sure that Ackman, Sequoia, ValueAct, Glenn Grenberg, and Lou Simpson are all incapable of doing due diligence and looking through accounting to real economics...

 

I will only short it once

 

1) Gio mentions that Pearson is an entrepreneur and a business man and there are 10 trillion pharma companies out there, ergo stock will provide 15% CAGR in perpetuity

2) 4-5 additional Tiger cubs buy it and trip  over themselves to divine higher price targets than the other

3) Ackman makes at least another billion front running them

4) the company seduces the ultimate unicorn, Warren Buffett

 

If all these happen I will short it. Until then, I'll let those far more knowledgeable and less jocular than I explain why this thang is worth 100 bilskys

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now



×
×
  • Create New...